<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620577</url>
  </required_header>
  <id_info>
    <org_study_id>FudanU</org_study_id>
    <nct_id>NCT04620577</nct_id>
  </id_info>
  <brief_title>The Influence of Antibiotics on the Incidence of Biliary Tract Infections After PTCD for Malignant Obstructive Jaundice</brief_title>
  <official_title>The Influence of Antibiotics on the Incidence of Biliary Tract Infections After PTCD for Malignant Obstructive Jaundice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xian-Jun Yu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the influence of antibiotics on the incidence of biliary tract infections&#xD;
      after PTCD for malignant obstructive jaundice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project designed a large-scale, single-center, prospective randomized controlled&#xD;
      clinical trial to explore the impact of antibiotics on the incidence of biliary tract&#xD;
      infections after PTCD with malignant obstructive jaundice. This study will provide&#xD;
      evidence-based medical evidence for the need for routine use of antibiotics to prevent&#xD;
      biliary tract infections after PTCD with malignant obstructive jaundice, and provide&#xD;
      references for clinicians to prevent patients from PTCD infections.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of patients with biliary tract infection after surgery</measure>
    <time_frame>October 2020 to June 2023</time_frame>
    <description>Incidence of patients with biliary tract infection after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decline rate of bilirubin in patients after PTCD</measure>
    <time_frame>October 2020 to June 2023</time_frame>
    <description>Decline rate of bilirubin in patients after PTCD</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>The Influence of Antibiotics on the Incidence of Biliary Tract Infections After PTCD for Malignant Obstructive Jaundice</condition>
  <arm_group>
    <arm_group_label>Antibiotic group</arm_group_label>
    <description>Infusion of ceftriaxone sodium needle (2g, solvent 100ml normal saline) within 1h before and 12h after PTCD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No-antibiotic group</arm_group_label>
    <description>Infusion of Normal saline within 1h before and 12h after PTCD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>antibiotic</intervention_name>
    <description>normal saline</description>
    <arm_group_label>Antibiotic group</arm_group_label>
    <arm_group_label>No-antibiotic group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with periampullary carcinoma and pancreatic head carcinoma who received PTCD&#xD;
        drainage.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-80 years old;&#xD;
&#xD;
          2. ECOG score 0-1 before operation;&#xD;
&#xD;
          3. Patients diagnosed as pancreatic head cancer and periampullary cancer according to&#xD;
             preoperative imaging, including ampullary cancer, extrahepatic bile duct cancer and&#xD;
             duodenal papillary cancer;&#xD;
&#xD;
          4. Bilirubin&gt;200 mmol/L before PTCD , and the duration of PTCD continuous drainage &gt;2&#xD;
             weeks;&#xD;
&#xD;
          5. Volunteer to participate and sign the informed consent form;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Decompensated liver cirrhosis, acute and chronic hepatitis and other diseases before&#xD;
             surgery;&#xD;
&#xD;
          2. A history of other malignant tumors before surgery;&#xD;
&#xD;
          3. Duration of preoperative PTCD drainage&lt;2 weeks;&#xD;
&#xD;
          4. Jaundice caused by other reasons besides cancer around the ampulla and cancer of the&#xD;
             head of the pancreas;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xianjun Yu, PhD</last_name>
    <phone>18019112906</phone>
    <email>yuxianjun@fudanpci.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mengqi Liu, MD</last_name>
    <phone>18019112906</phone>
    <email>liumengqi@fudanpci.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xian-Jun Yu, M.D., Ph.D.</last_name>
      <phone>+86-21-6417-5590</phone>
      <email>yuxianjun@fudanpci.org</email>
    </contact>
    <contact_backup>
      <last_name>Wen-Quan Wang, M.D., Ph.D.</last_name>
      <phone>+86-21-6417-5590</phone>
      <email>wangwenquan@fudanpci.org</email>
    </contact_backup>
    <investigator>
      <last_name>Xianjun Yu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xian-Jun Yu</investigator_full_name>
    <investigator_title>President of Shanghai Pancreatic Cancer Institute</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Jaundice</mesh_term>
    <mesh_term>Jaundice, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

